Gracell Biotechnologies Financials

Gracell Biotechnologies Stock Summary

Gracell Biotechnologies competes with Monte Rosa, Design Therapeutics, Erasca, NextCure, and CytomX Therapeutics. Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the Peoples Republic of China. The company was founded in 2017 and is headquartered in Suzhou, China. Gracell Biotechnologies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 348 people.

Gracell Biotechnologies Key Financial Ratios

Gracell Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Gracell Biotechnologies's current stock value. Our valuation model uses many indicators to compare Gracell Biotechnologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Gracell Biotechnologies competition to find correlations between indicators driving Gracell Biotechnologies's intrinsic value. More Info.Gracell Biotechnologies is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Gracell Biotechnologies by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

If you are still planning to invest in Gracell Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gracell Biotechnologies' history and understand the potential risks before investing.